// App-Quantinova.ai

676 : A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04

Researchers

Presenter

  • Ezra Cohen

Principal Investigators

  • Kevin Harrington

  • Jean-Pascal Machiels

  • Sjoukje Oosting

  • Bhumsuk Keam

  • Beatriz Cirauqui

  • Annette Lim

  • Keun-Wook Lee

  • Tim Welliver

  • Christine Ju

  • Feng Jin

  • Alison Forgie

  • Jaume Pons

  • Sophia Randolph

  • Athanasios Tsiatis

Medical Centers

  • Seoul National University Hospital, Seoul, Korea

  • Peter MacCallum Cancer Centre, Parkville, Australia.

  • University of California, San Diego, La Jolla, CA

  • Royal Marsden Hospital, Sutton, UK

  • University Medical Center Groningen, Nijmegen, Netherlands

  • Institut Catal dOncologia Badalona, Badalona, Spain

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

Locations

  • Republic of South Korea

  • United States

  • United Kingdom

  • Spain

  • Australia

  • Netherlands

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • Cisplatin

  • ALX148

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacodynamics

  • Open Label

  • Non-Comparative

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved